Jiangsu Hengrui Medicine Co., Ltd. (SHA: 600276) has received approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its SHR-A2102 in combination with SHR-8068 in patients with advanced solid tumors.
SHR-A2102 is an internally developed antibody-drug conjugate (ADC) that targets Nectin-4, a protein whose high expression is linked to tumor progression and poor prognosis. Currently in Phase I clinical trials in China, SHR-A2102 utilizes a topoisomerase inhibitor (TOPi) as its payload. A comparable Nectin-4 targeted ADC on the global market is Padcev (enfortumab vedotin) from Pfizer and Seagen.
SHR-8068 is an in-licensed monoclonal antibody (mAb) that targets CTLA-4. There are only two similar products available worldwide: ipilimumab and tremelimumab.- Flcube.com
